BIO-RAD LABORATORIES-A (BIO)

Bio-Rad Laboratories Larger Than S&P 500 Component Celanese

Bio-Rad’s Management to Host Investor Meetings at Citi's 2024 Global Healthcare Conference

Notable Two Hundred Day Moving Average Cross - BIO

Bio-Rad's Management to Participate in Fireside Chat During UBS Global Healthcare Conference

Bio-Rad Reports Third-Quarter 2024 Financial Results

Bio-Rad to Report Third Quarter 2024 Financial Results on Wednesday, October 30, 2024

Monday Sector Laggards: Healthcare, Financial

Palantir Stock Will Join the S&P 500 in September. History Says It Could Soar Afterward.

History says Palantir stock could soar after its inclusion in the S&P 500.

Wesco International Moves Up In Market Cap Rank, Passing Bio-Rad Laboratories

Applied Industrial Technologies Moves Up In Market Cap Rank, Passing Bio-Rad Laboratories

Palantir Technologies, Dell Technologies, and Erie Indemnity Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

/PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior...

Palantir, Dell Will Join The S&P 500. The AI Stocks Are Jumping.

Palantir, Dell Technologies and Erie Indemnity will join the S&P 500 on Sept. 23. All three stocks jumped late Friday.

Bio-Rad’s Management to Participate in Fireside Chat During Wells Fargo’s 2024 Healthcare Conference

Bio-Rad Appoints Jon DiVincenzo President, Chief Operating Officer

Middleby Larger Than S&P 500 Component Bio-Rad Laboratories

Commerce Bancshares Larger Than S&P 500 Component Bio-Rad Laboratories

Bio-Rad Reports Second-Quarter 2024 Financial Results

Agree To Purchase Bio-Rad Laboratories At $280, Earn 8.2% Annualized Using Options

Bio-Rad to Report Second Quarter Financial Results on Thursday, August 1, 2024

Bullish Two Hundred Day Moving Average Cross - BIO

Confluent Larger Than S&P 500 Component Bio-Rad Laboratories

Houlihan Lokey Larger Than S&P 500 Component Bio-Rad Laboratories

OncoCyte’s (NASDAQ:OCX) Innovative Approach: Potential in Precision Diagnostics

OncoCyte's Innovative Approach: Potential in Precision Diagnostics

Chronic conditions such as organ transplant rejection and cancer represent significant challenges in modern healthcare, demanding precise diagnostic tools for effective management and treatment. For organ transplant patients, the risk of graft rejection remains a persistent threat, necessitating continuous monitoring to ensure long-term success. Similarly, the complexity of cancer requires advanced diagnostics to tailor treatments to individual patients, optimizing therapeutic efficacy while minimizing adverse effects.

Bio-Rad Names Anette Engelhardt Executive Vice President and President of Clinical Diagnostics Group

AutoNation Larger Than S&P 500 Component Bio-Rad Laboratories

Bio-Rad’s Management to Participate in Fireside Chat During Jefferies Global Healthcare Conference

Summit Materials Moves Up In Market Cap Rank, Passing Bio-Rad Laboratories

HealthEquity Moves Up In Market Cap Rank, Passing Bio-Rad Laboratories

Popular Larger Than S&P 500 Component Bio-Rad Laboratories

Meritage Homes Moves Up In Market Cap Rank, Passing Bio-Rad Laboratories

Olin Larger Than S&P 500 Component Bio-Rad Laboratories

Bio-Rad Laboratories is Now Oversold (BIO)

BIO Stock Earnings: Bio-Rad Laboratories Beats EPS, Misses Revenue for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Bio-Rad Laboratories (NYSE:BIO) just reported results for the first quarter of ...